288 related articles for article (PubMed ID: 29254858)
1. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial.
Shepstone L; Lenaghan E; Cooper C; Clarke S; Fong-Soe-Khioe R; Fordham R; Gittoes N; Harvey I; Harvey N; Heawood A; Holland R; Howe A; Kanis J; Marshall T; O'Neill T; Peters T; Redmond N; Torgerson D; Turner D; McCloskey E;
Lancet; 2018 Feb; 391(10122):741-747. PubMed ID: 29254858
[TBL] [Abstract][Full Text] [Related]
2. Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures-A Post Hoc Analysis of the SCOOP Study.
McCloskey E; Johansson H; Harvey NC; Shepstone L; Lenaghan E; Fordham R; Harvey I; Howe A; Cooper C; Clarke S; Gittoes N; Heawood A; Holland R; Marshall T; O'Neill TW; Peters TJ; Redmond N; Torgerson D; Kanis JA;
J Bone Miner Res; 2018 Jun; 33(6):1020-1026. PubMed ID: 29480960
[TBL] [Abstract][Full Text] [Related]
3. Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study.
Söreskog E; Borgström F; Shepstone L; Clarke S; Cooper C; Harvey I; Harvey NC; Howe A; Johansson H; Marshall T; O'Neill TW; Peters TJ; Redmond NM; Turner D; Holland R; McCloskey E; Kanis JA;
Osteoporos Int; 2020 Aug; 31(8):1499-1506. PubMed ID: 32239237
[TBL] [Abstract][Full Text] [Related]
4. Screening for high hip fracture risk does not impact on falls risk: a post hoc analysis from the SCOOP study.
Condurache CI; Chiu S; Chotiyarnwong P; Johansson H; Shepstone L; Lenaghan E; Cooper C; Clarke S; Khioe RFS; Fordham R; Gittoes N; Harvey I; Harvey NC; Heawood A; Holland R; Howe A; Kanis JA; Marshall T; O'Neill TW; Peters TJ; Redmond NM; Torgerson D; Turner D; McCloskey E;
Osteoporos Int; 2020 Mar; 31(3):457-464. PubMed ID: 31960099
[TBL] [Abstract][Full Text] [Related]
5. Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis.
Merlijn T; Swart KMA; van der Horst HE; Netelenbos JC; Elders PJM
Osteoporos Int; 2020 Feb; 31(2):251-257. PubMed ID: 31838551
[TBL] [Abstract][Full Text] [Related]
6. The Effect of a Screening and Treatment Program for the Prevention of Fractures in Older Women: A Randomized Pragmatic Trial.
Merlijn T; Swart KM; van Schoor NM; Heymans MW; van der Zwaard BC; van der Heijden AA; Rutters F; Lips P; van der Horst HE; Niemeijer C; Netelenbos JC; Elders PJ
J Bone Miner Res; 2019 Nov; 34(11):1993-2000. PubMed ID: 31220365
[TBL] [Abstract][Full Text] [Related]
7. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
8. A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study.
Shepstone L; Fordham R; Lenaghan E; Harvey I; Cooper C; Gittoes N; Heawood A; Peters T; O'Neill T; Torgerson D; Holland R; Howe A; Marshall T; Kanis J; McCloskey E
Osteoporos Int; 2012 Oct; 23(10):2507-15. PubMed ID: 22314936
[TBL] [Abstract][Full Text] [Related]
9. Systematic screening using FRAX
Parsons CM; Harvey N; Shepstone L; Kanis JA; Lenaghan E; Clarke S; Fordham R; Gittoes N; Harvey I; Holland R; Redmond NM; Howe A; Marshall T; Peters TJ; Torgerson D; O'Neill TW; McCloskey E; Cooper C;
Osteoporos Int; 2020 Jan; 31(1):67-75. PubMed ID: 31606826
[TBL] [Abstract][Full Text] [Related]
10. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
11. Can frailty in conjunction with FRAX identify additional women at risk of fracture - a longitudinal cohort study of community dwelling older women.
Bartosch P; Malmgren L
BMC Geriatr; 2022 Dec; 22(1):951. PubMed ID: 36494774
[TBL] [Abstract][Full Text] [Related]
12. The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study.
Turner DA; Khioe RFS; Shepstone L; Lenaghan E; Cooper C; Gittoes N; Harvey NC; Holland R; Howe A; McCloskey E; O'Neill TW; Torgerson D; Fordham R;
J Bone Miner Res; 2018 May; 33(5):845-851. PubMed ID: 29470854
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study.
Rubin KH; Rothmann MJ; Holmberg T; Høiberg M; Möller S; Barkmann R; Glüer CC; Hermann AP; Bech M; Gram J; Brixen K
Osteoporos Int; 2018 Mar; 29(3):567-578. PubMed ID: 29218381
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of osteoporosis screening strategies for hip fracture prevention in older Chinese people: a decision tree modeling study in the Mr. OS and Ms. OS cohort in Hong Kong.
Su Y; Lai FTT; Yip BHK; Leung JCS; Kwok TCY
Osteoporos Int; 2018 Aug; 29(8):1793-1805. PubMed ID: 29774400
[TBL] [Abstract][Full Text] [Related]
16. The Added Value of SARC-F to Prescreening Using FRAX for Hip Fracture Prevention in Older Community Adults.
Su Y; Woo JW; Kwok TCY
J Am Med Dir Assoc; 2019 Jan; 20(1):83-89. PubMed ID: 30314676
[TBL] [Abstract][Full Text] [Related]
17. Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010.
Klop C; Gibson-Smith D; Elders PJ; Welsing PM; Leufkens HG; Harvey NC; Bijlsma JW; van Staa TP; de Vries F
Osteoporos Int; 2015 Jul; 26(7):1919-28. PubMed ID: 25963232
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of the Screening for the Primary Prevention of Fragility Hip Fracture in Spain Using FRAX
Martin-Sanchez M; Comas M; Posso M; Louro J; Domingo L; Tebé C; Castells X; Espallargues M
Calcif Tissue Int; 2019 Sep; 105(3):263-270. PubMed ID: 31172231
[TBL] [Abstract][Full Text] [Related]
19. Association of Mental Disorders and Related Medication Use With Risk for Major Osteoporotic Fractures.
Bolton JM; Morin SN; Majumdar SR; Sareen J; Lix LM; Johansson H; Odén A; McCloskey EV; Kanis JA; Leslie WD
JAMA Psychiatry; 2017 Jun; 74(6):641-648. PubMed ID: 28423154
[TBL] [Abstract][Full Text] [Related]
20. Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density.
Klop C; de Vries F; Bijlsma JW; Leufkens HG; Welsing PM
Ann Rheum Dis; 2016 Dec; 75(12):2095-2100. PubMed ID: 26984006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
